Ocular Therapeutix Anticipates DEXTENZA Net Product Revenue Guidance For FY23 To Come In At The Upper End Of The Current $55M-$60M Range
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix expects its DEXTENZA net product revenue guidance for FY23 to be at the upper end of the current $55M-$60M range.
November 08, 2023 | 1:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's FY23 revenue guidance for its product DEXTENZA is expected to reach the upper end of the $55M-$60M range.
The news directly pertains to Ocular Therapeutix and its product DEXTENZA. The company's anticipation of higher revenues indicates a positive outlook for the product and the company, which could potentially lead to a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100